Here are the pharmaceutical companies best prepared for AI

How well prepared are pharmaceutical companies in the field of artificial intelligence? That is what a new analysis has tried to evaluate.

Anna Törner: The minute between life and death

“I have never told anyone about this day that happened more than 20 years ago. But I sometimes reflect on what happened, on what might have happened. When I try...

Helena Strigård: The rise of the community

Sweden Bio´s CEO is looking back at the last decade of development in the industry. Something has shifted in the interdependence between small and larger companies.

Sweden and Denmark – this is how they choose their strategies

Scandinavia’s two major powers in pharmaceutical research have developed strategies for growth in life science, and both countries aim to become world leaders.

Pilots want to live too

A surprising discovery about the immune system in cases of cancer

Professor Göran Jönsson is trying to understand why some patients benefit from immunotherapies while others don’t. A couple of years ago, he made a surprising d...

EU Pharmaceutical Legislation Reform

The EU's Pharmaceutical Legislation Reform, proposed by the commission within the European Health Union, aims to establish a citizen-centric framework to enhanc...

Swedish and Ukrainian Medical Product Agencies sign an agreement

The Directors-General of the Swedish and Ukrainian Medical Products Agencies have signed a cooperation agreement.

Brexit looking back and looking forward

More than 3 years have passed after the vote and there is still uncertainty around the outcome although the UK December 12 election set a clearer course towards...

Study: Semaglutide tablet produces weight loss

The pharmaceutical semaglutide is effective for weight loss even when given in tablet form, according to a phase 3 study.

Peptider kan bli framtidens läkemedel

Tyska forskare rapporterar ett genombrott i arbetet med att göra små proteiner tillgängliga som läkemedel i pillerform.

Sov som en björn – och undvik blodproppar

Minskning av ett visst blodplättsprotein tycks ha en nyckelroll när det gäller att förhindra blodproppar, enligt forskning vid bland annat Universitetssjukhuset...

Norwegian company wins bidding battle for Sensidose

The lengthy battle to acquire medical device company Sensidose is apparently over. Generic medicines company EQL Pharma is pulling out, selling its shares and l...

Ny teknik förenklar 3D-printing av läkemedel

Vilka är de senaste trenderna inom 3D-utskrifter av läkemedel? Thomas Kipping ska besvara den frågan på Life Science Swedens möte.

Svensk-danskt event blir e-möte

I september anordnas Life Science Swedens två event The Future of Swedish & Danish Life Science och New Updates in Drug Formulation & Bioavailability för första...

BioVentureHub CEO: “Companies with a high degree of interaction achieve greater success”

For the first time since its inception, AstraZeneca’s BioVentureHub can now recruit new companies, as some of its tenants have grown significantly and are leavi...

New Updates in Drug Formulation & Bioavailability: AI hett område

AI är en av de revolutionerande tekniker som kommer att omforma läkemedelsindustrin, säger Anders Broo, AstraZeneca, Mölndal.

Tougher competition as the Novo Nordisk Foundation broadens its programme

Søren Nedergaard has worked with innovation at the Danish Government Offices and the University of Copenhagen. Today, he is COO of the Novo Nordisk Foundation, ...

Linköpingsforskare utvecklar ny klass av antibiotika

Forskare vid Linköpings universitet hoppas i framtiden kunna använda en grupp av läkemedel som ofta används vid behandling av cancer för att bekämpa bakterieinf...

AstraZeneca moves to brewery quarters in central Copenhagen

AstraZeneca in Denmark is moving its business into central Copenhagen and the old brewery quarters in Carlsberg Byen.

Glad sommar! – och chefredaktörens lästips

Life Science Swedens chefredaktör sammanfattar året hittills och ger lästips inför sommaren.

An industry emerging from crisis

"Scanlab is normally indicative of the status of investment incentives in the laboratory industry "

We will now publish more news in English – and offer yet another newsletter

Starting next week, Life Science Sweden will begin offering a newsletter entirely in English.

The new Astra Zeneca CEO: “An incredibly exciting phase”

Almost 27 years have passed since Per Alfredsson from Södertälje stepped into Astra Zeneca as a newly hired engineer. After countless different roles, including...